We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+39.96%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.39B
AUM Growth
+$491M
Cap. Flow
-$128M
Cap. Flow %
-3.78%
Top 10 Hldgs %
67.91%
Holding
89
New
9
Increased
10
Reduced
15
Closed
13

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$99.2M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$75.1M
3
GOSS icon
Gossamer Bio
GOSS
+$51.6M
4
KYMR icon
Kymera Therapeutics
KYMR
+$21M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$13.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$118M
2
RVMD icon
Revolution Medicines
RVMD
+$54.4M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$53.7M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$43.5M
5
ARGX icon
argenx
ARGX
+$39.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.27%
2 Financials 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYGR icon
26
Voyager Therapeutics
VYGR
$187M
$28.1M 0.83%
4,753,907
– –
CRNX icon
27
Crinetics Pharmaceuticals
CRNX
$8.87B
$26.1M 0.77%
1,330,263
– –
JANX icon
28
Janux Therapeutics
JANX
$950M
$19.2M 0.57%
1,421,319
– –
KYMR icon
29
Kymera Therapeutics
KYMR
$9.05B
$17.3M 0.51%
+796,093
New +$21M
TNGX icon
30
Tango Therapeutics
TNGX
$4.35B
$15.2M 0.45%
4,201,414
+1,899,349
+83% +$8.11M
CGEM icon
31
Cullinan Oncology
CGEM
$1.07B
$14.7M 0.43%
1,143,218
-26,671
-2% -$359K
VTYX
32
DELISTED
Ventyx Biosciences
VTYX
$14M 0.41%
400,000
-900,000
-69% -$19.9M
KDNY
33
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$13.6M 0.4%
690,000
– –
AKUS
34
DELISTED
Akouos Inc
AKUS
$13.4M 0.39%
1,975,984
– –
CNTA
35
DELISTED
Centessa Pharmaceuticals
CNTA
$13M 0.38%
3,236,352
+2,944,032
+1,007% +$13.5M
OVID icon
36
Ovid Therapeutics
OVID
$439M
$11.3M 0.33%
6,117,400
– –
ORIC icon
37
Oric Pharmaceuticals
ORIC
$1.24B
$10.9M 0.32%
3,418,068
– –
PSTX
38
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$9.36M 0.28%
+2,650,000
New +$8.76M
ARQT icon
39
Arcutis Biotherapeutics
ARQT
$3.48B
$7.94M 0.23%
415,322
-480,181
-54% -$10.9M
NGM
40
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$7.08M 0.21%
541,108
– –
HOOK
41
DELISTED
HOOKIPA Pharma
HOOK
$6.7M 0.2%
500,000
– –
DTIL icon
42
Precision BioSciences
DTIL
$187M
$6.55M 0.19%
167,866
– –
ARGX icon
43
argenx
ARGX
$55.6B
$6.19M 0.18%
17,527
-107,473
-86% -$39.8M
GRCL
44
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$6.19M 0.18%
1,921,310
– –
RNAC icon
45
Cartesian Therapeutics
RNAC
$229M
$5.74M 0.17%
116,667
– –
GERN icon
46
Geron
GERN
$949M
$5.39M 0.16%
2,301,980
-11,867,008
-84% -$26.6M
AVEO
47
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$5.35M 0.16%
650,489
+3,000
+0.5% +$23K
ERAS icon
48
Erasca
ERAS
$6.55B
$5.29M 0.16%
678,441
– –
LENZ
49
LENZ Therapeutics
LENZ
$179M
$5.01M 0.15%
226,019
+59,993
+36% +$1.43M
JYAC
50
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.99M 0.15%
500,000
– –
1
2
3 4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q3 2022 Portfolio in Review

As of Q3 2022, EcoR1 Capital held 89 positions worth $3.39B, up 17% from $2.9B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital withdrew a net $128M in Q3 2022, closing 13 positions and reducing 15 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $43.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

Against the trend, EcoR1 Capital opened a new position in SpringWorks Therapeutics worth $98.7M.

  • EcoR1 Capital's largest Q3 2022 buy was SpringWorks Therapeutics: 3,460,208 shares worth $98.7M.
  • EcoR1 Capital added most to Centessa Pharmaceuticals in Q3 2022, an estimated $13.5M increase.
  • EcoR1 Capital's biggest Q3 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $118M.
  • EcoR1 Capital fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2022, selling an estimated $43.5M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $3.39B portfolio in Q3 2022.
  • EcoR1 Capital opened 9 new positions and closed 13 in Q3 2022.
  • EcoR1 Capital's portfolio value rose 17% quarter-over-quarter to $3.39B.

Based on EcoR1 Capital's 13F filing for Q3 2022, filed 14 Nov 2022.